Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.
तुलना करने के लिए मीट्रिक्स | ATRA | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधATRAपीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −0.4x | −0.6x | −0.5x | |
PEG अनुपात | −0.01 | −0.01 | 0.00 | |
क़ीमत/बुक | −0.4x | 2.1x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 0.3x | 13.1x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | 129.4% | 311.1% | 53.0% | |
उचित मूल्य अपसाइड | अनलॉक करें | 11.5% | 8.9% | अनलॉक करें |